Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer

[1]  M. Raica,et al.  Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. , 2008, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[2]  J. Tonn,et al.  Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature , 2008, Brain pathology.

[3]  G. Garcı́a-Cardeña,et al.  Regulation of arterial-venous differences in tumor necrosis factor responsiveness of endothelial cells by anatomic context. , 2008, The American journal of pathology.

[4]  M. Shindoh,et al.  Understanding tumor endothelial cell abnormalities to develop ideal anti‐angiogenic therapies , 2008, Cancer science.

[5]  Mariaelena Pierobon,et al.  Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.

[6]  I. Fidler,et al.  Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. , 2007, Neoplasia.

[7]  I. Fidler,et al.  Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. , 2007, The American journal of pathology.

[8]  D. Fliser,et al.  Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. , 2007, Arthritis and rheumatism.

[9]  S. Jalkanen,et al.  VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Andrei Iagaru,et al.  Molecular imaging can accelerate anti-angiogenic drug development and testing , 2007, Nature Clinical Practice Oncology.

[11]  Jordan S. Pober,et al.  Evolving functions of endothelial cells in inflammation , 2007, Nature Reviews Immunology.

[12]  J. Rak,et al.  Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. , 2007, The American journal of pathology.

[13]  Yihai Cao,et al.  Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. , 2007, The Journal of clinical investigation.

[14]  D. Hicklin,et al.  Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy , 2007, Clinical Cancer Research.

[15]  A. Kribben,et al.  Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. , 2007, American journal of physiology. Renal physiology.

[16]  Arjan W. Griffioen,et al.  Tumour vascularization: sprouting angiogenesis and beyond , 2007, Cancer and Metastasis Reviews.

[17]  M. van Meurs,et al.  EARLY ORGAN-SPECIFIC ENDOTHELIAL ACTIVATION DURING HEMORRHAGIC SHOCK AND RESUSCITATION , 2007, Shock.

[18]  C. Kallenberg,et al.  Site-Specific Inhibition of Glomerulonephritis Progression by Targeted Delivery of Dexamethasone to Glomerular Endothelium , 2007, Molecular Pharmacology.

[19]  R. Stan.  Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis , 2007, Journal of cellular and molecular medicine.

[20]  S. Seaman,et al.  Genes that distinguish physiological and pathological angiogenesis. , 2007, Cancer cell.

[21]  Tracy T Batchelor,et al.  VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. , 2007, Trends in molecular medicine.

[22]  Po-Len Liu,et al.  High Glucose Impairs Early and Late Endothelial Progenitor Cells by Modifying Nitric Oxide–Related but Not Oxidative Stress–Mediated Mechanisms , 2007, Diabetes.

[23]  T. Roskams,et al.  High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT–PCR mRNA expression profile , 2007, British Journal of Cancer.

[24]  D. Hicklin,et al.  Simultaneous blockade of VEGFR‐1 and VEGFR‐2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation , 2007, International journal of cancer.

[25]  Shayn M Peirce,et al.  EphB4 Expression Along Adult Rat Microvascular Networks: EphB4 Is More Than a Venous Specific Marker , 2007, Microcirculation.

[26]  George Coukos,et al.  Tumor vascular proteins as biomarkers in ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. de Martin,et al.  Resolution of inflammation: Intracellular feedback loops in the endothelium , 2007, Thrombosis and Haemostasis.

[28]  William C. Aird,et al.  Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms , 2007, Circulation research.

[29]  W. Aird.  Phenotypic Heterogeneity of the Endothelium: II. Representative Vascular Beds , 2007, Circulation research.

[30]  D. Hume,et al.  Histone Deacetylase Inhibitor Reduces Monocyte Adhesion to Endothelium Through the Suppression of Vascular Cell Adhesion Molecule-1 Expression , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Terri L. McKay,et al.  A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. , 2006, Microvascular research.

[32]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[33]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[34]  C. Ferran.  Protective Genes in the Vessel Wall: Modulators of Graft Survival and Function , 2006, Transplantation.

[35]  H. Dvorak,et al.  Permeability properties of tumor surrogate blood vessels induced by VEGF-A , 2006, Laboratory Investigation.

[36]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[37]  L. V. D. Heuvel,et al.  Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. , 2006, Kidney international.

[38]  F. Bosman,et al.  Immunohistochemical Expression of Endothelial Markers CD31, CD34, von Willebrand Factor, and Fli-1 in Normal Human Tissues , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[39]  S. Groshen,et al.  Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. , 2006, The Journal of urology.

[40]  W. Aird.  Mechanisms of endothelial cell heterogeneity in health and disease. , 2006, Circulation research.

[41]  D. Dumont,et al.  Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. , 2005, The American journal of pathology.

[42]  S. Madden,et al.  Plasmalemmal Vesicle Associated Protein-1 Is a Novel Marker Implicated in Brain Tumor Angiogenesis , 2005, Clinical Cancer Research.

[43]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[44]  A. Sood,et al.  Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors , 2005, Clinical Cancer Research.

[45]  R. Jain,et al.  NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. , 2005, The Journal of clinical investigation.

[46]  Chryso Kanthou,et al.  Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.

[47]  I. Dreher,et al.  The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis , 2005, Oncogene.

[48]  A. Bikfalvi,et al.  Molecular mechanisms of tumor vascularization. , 2005, Critical reviews in oncology/hematology.

[49]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Ozawa,et al.  Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. , 2005, The American journal of pathology.

[51]  J. Pober,et al.  Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl-2-transduced endothelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[53]  Dhara N. Amin,et al.  Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.

[54]  Pieter Wesseling,et al.  Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option , 2004, Clinical Cancer Research.

[55]  Oswald Wagner,et al.  Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. , 2004, The New England journal of medicine.

[56]  L. Ellis,et al.  Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. , 2004, Journal of the National Cancer Institute.

[57]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[58]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[59]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[60]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[61]  H. Dvorak,et al.  Ultrastructural Localization of Platelet Endothelial Cell Adhesion Molecule (PECAM-1, CD31) in Vascular Endothelium , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[62]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[63]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[64]  David Botstein,et al.  Endothelial cell diversity revealed by global expression profiling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[66]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.

[67]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[68]  J. Nelson,et al.  The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.

[69]  Wadih Arap,et al.  Probing the structural and molecular diversity of tumor vasculature. , 2002, Trends in molecular medicine.

[70]  K. Müller,et al.  Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. , 2002, Experimental and molecular pathology.

[71]  A. Bankfalvi,et al.  Human endomucin: distribution pattern, expression on high endothelial venules, and decoration with the MECA-79 epitope. , 2002, The American journal of pathology.

[72]  J. Cherrington,et al.  SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  R. Jain,et al.  Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[75]  G. Hämmerling,et al.  Transformation of the microvascular system during multistage tumorigenesis , 2002, International journal of cancer.

[76]  Lei Xu,et al.  Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.

[77]  L. Ellis,et al.  In vivo intracellular signaling as a marker of antiangiogenic activity. , 2001, Cancer research.

[78]  J. Folkman,et al.  Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. , 2001, Journal of the National Cancer Institute.

[79]  M. Maio,et al.  Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies , 2001, Journal of cellular physiology.

[80]  P. Carmeliet,et al.  Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.

[81]  P. Carmeliet,et al.  Molecular mechanisms of blood vessel growth. , 2001, Cardiovascular research.

[82]  G. Yancopoulos,et al.  Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. , 2001, Developmental biology.

[83]  P. Kubes,et al.  A Role for Platelets and Endothelial Selectins in Tumor Necrosis Factor-&agr;–Induced Leukocyte Recruitment in the Brain Microvasculature , 2000, Circulation research.

[84]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[85]  Cherrington,et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.

[86]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[87]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[88]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[89]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[90]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[91]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[92]  C. Bucana,et al.  Spatial and temporal expression of angiogenic molecules during tumor growth and progression. , 1998, Oncology research.

[93]  W. Cavenee,et al.  Host microvasculature influence on tumor vascular morphology and endothelial gene expression. , 1998, The American journal of pathology.

[94]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[95]  F. Dignat-George,et al.  Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. , 1997, Tissue antigens.

[96]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[97]  R K Jain,et al.  Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.

[98]  C. Garlanda,et al.  Heterogeneity of endothelial cells. Specific markers. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[99]  CeciliaGarlanda,et al.  Heterogeneity of Endothelial Cells , 1997 .

[100]  M. Cooper,et al.  Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury , 1997, Diabetologia.

[101]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[102]  C. Bucana,et al.  Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. , 1994, The American journal of pathology.

[103]  S. Jalkanen,et al.  Induction and function of vascular adhesion protein-1 at sites of inflammation , 1993, The Journal of experimental medicine.

[104]  C. Haudenschild,et al.  Preservation of thrombomodulin antigen on vascular and extravascular surfaces. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[105]  G. Heppner,et al.  Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA 100. , 1984, Cancer research.

[106]  J. Denekamp,et al.  Endothelial proliferation in tumours and normal tissues: continuous labelling studies. , 1984, British Journal of Cancer.

[107]  I. Fidler,et al.  Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.

[108]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[109]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[110]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[111]  H. Dvorak,et al.  Tumor Blood Vessels , 2008 .

[112]  Lawrence D. True,et al.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases , 2007, Clinical & Experimental Metastasis.

[113]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[114]  C. Patterson.  Endothelial Biomedicine: Endothelial Cell Differentiation and Vascular Development in Mammals , 2007 .

[115]  T. Stevens.  Endothelial Biomedicine: Microheterogeneity of Lung Endothelium , 2007 .

[116]  H. Dvorak.  Endothelial Biomedicine: Tumor Blood Vessels , 2007 .

[117]  Ming-Yu Liu,et al.  Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas. , 2006, International immunopharmacology.

[118]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[119]  E. van Marck,et al.  Endothelial cell apoptosis in the context of quantification of angiogenesis in solid human adenocarcinomas: a novel double immunolabelling technique to identify endothelial cell apoptosis. , 2006, European journal of cancer.

[120]  P. Rieckmann,et al.  Isolation and Culture of Microvascular Endothelial Cells from Gliomas of Different WHO Grades , 2005, Journal of Neuro-Oncology.

[121]  A. Foss,et al.  Endothelial Cells of Tumor Vessels: Abnormal but not Absent , 2004, Cancer and Metastasis Reviews.

[122]  G. Garcı́a-Cardeña,et al.  Early adaptive responses of the vascular wall during venous arterialization in mice. , 2004, The American journal of pathology.

[123]  J. Papadimitriou,et al.  Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases , 2004, Clinical & Experimental Metastasis.

[124]  C. Betsholtz,et al.  Analysis of Mural Cell Recruitment to Tumor Vessels , 2002, Circulation.

[125]  C. Fu,et al.  Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[126]  Dian Feng,et al.  Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.

[127]  Martin R. Schneider,et al.  PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration , 2000 .

[128]  Baljit Singh,et al.  Vascular expression of the αvβ3-integrin in lung and other organs , 2000 .

[129]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[130]  L. Ellis,et al.  In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. , 1995, The American journal of pathology.

[131]  J. Winer,et al.  Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. , 1992, The Journal of clinical investigation.

[132]  G. Heppner.  Tumor heterogeneity. , 1984, Cancer research.